TMDX
$113.90+0.18 (+0.16%)
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.
Recent News
TransMedics Extends Decline as Selling Pressure Builds
Recent weakness continues despite supportive analyst view
Is TransMedics Group, Inc. (TMDX) A Good Stock To Buy Now?
Is TMDX a good stock to buy? We came across a bullish thesis on TransMedics Group, Inc. on The Cash Flow Compounder’s Substack. In this article, we will summarize the bulls’ thesis on TMDX. TransMedics Group, Inc.’s share was trading at $129.61 as of March 6th. TMDX’s trailing and forward P/E were 26.61 and 56.18 respectively according to […]
Analysts Raise TransMedics Group, Inc. (TMDX) Price Targets After Q4 Results
TransMedics Group, Inc. (NASDAQ:TMDX) is one of the best under-the-radar stocks to buy according to hedge funds. On February 25, Baird raised its price target on TransMedics Group, Inc. (NASDAQ:TMDX) from $154 to $168 and kept its Outperform rating on the stock. Baird updated its model after the company reported fourth-quarter results that surpassed expectations […]
Assessing TransMedics Group (TMDX) Valuation After Recent Short Term Share Price Weakness
TransMedics Group (TMDX) has drawn investor attention after recent trading saw the stock close at US$129.61, with short term returns under pressure even as longer term performance and current fundamentals invite closer scrutiny. See our latest analysis for TransMedics Group. The recent 1 day share price decline of 7.47%, alongside a 7 day share price return of negative 10.77%, contrasts with a 1 year total shareholder return of 92.13%. This pattern suggests strong longer term momentum even as...
TransMedics Stock Is Up 104% Over the Last Year: Is It Too Late to Buy for 2026?
TransMedics continues to reinvent the organ transplant industry, but the market insists the stock is "overvalued" now.